
Core Insights - IN8bio, Inc. announced new data on its proprietary γδ T cell manufacturing program, showcasing advancements in their technology at the ISCT 2025 Annual Meeting, which earned them the Host Region Abstract Award [1][7] - The DeltEx™ Allo manufacturing process effectively induces donor-derived T cells to express γδ T cell receptors associated with enhanced cancer cytotoxicity, confirmed by gene expression profiling across multiple batches [2][8] - The company maintains hands-on control over all manufacturing steps, which is crucial for the development of safe and effective cellular therapies, positioning IN8bio as a leader in γδ T cell manufacturing [3][7] Key Findings from INB-100 Study - The INB-100 clinical trial demonstrated durable long-term remissions in adult AML patients with complex disease characteristics, with γδ T cells showing long-term expansion and persistence for over one year [5][8] - The manufacturing program has been automated, allowing for rapid and reproducible production of cryopreserved cell therapy doses, with the trial continuing to enroll an expansion cohort at the recommended Phase 2 dose [5] - All analyzed clinical batches showed a consistent shift from αβ-TCR to γδ-TCR dominance, indicating that the manufacturing process drives the final TCR composition rather than the donor material [8] Company Overview - IN8bio is focused on developing γδ T cell-based immunotherapies for cancer and autoimmune diseases, with its lead program, INB-100, targeting acute myeloid leukemia using haplo-matched allogeneic γδ T cells [6] - The company is also exploring autologous DeltEx DRI γδ T cells for glioblastoma and advancing novel γδ T cell engagers for potential oncology and autoimmune indications [6]